Cenderitide: Structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 2, Issue 2, 2016, Pages 98-105

  Lee, Candace Y W ^a   Huntley, Brenda K ^a   McCormick, Daniel J ^a   Ichiki, Tomoko ^a   Sangaralingham, S Jeson ^a   Lisy, Ondrej ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

C type natriuretic peptide; Canine; CD NP; Chimeric natriuretic peptide

Indexed keywords

CARBOXYL TERMINUS OF DENDROASPIS NATRIURETIC PEPTIDE; CENDERITIDE; CYCLIC GMP; HEAT STABLE ENTEROTOXIN RECEPTOR AGONIST; NATRIURETIC PEPTIDE TYPE C DERIVATIVE; PARTICULATE GUANYLYL CYCLASE A RECEPTOR ACTIVATION; PARTICULATE GUANYLYL CYCLASE B RECEPTOR ACTIVATION; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C; SNAKE VENOM; URINARY TRACT AGENT;

AMINO ACID SEQUENCE; ARTICLE; CANINE MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; EX VIVO STUDY; GLOMERULUS; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MALE; NATRIURESIS; PRIORITY JOURNAL; URINARY EXCRETION; AGONISTS; ANIMAL; CHEMISTRY; DENDROASPIS; DOG; DRUG DESIGN; DRUG EFFECTS; HEK293 CELL LINE; KIDNEY FUNCTION TEST; STRUCTURE ACTIVITY RELATION; URINE;

ANIMALS; CYCLIC GMP; DENDROASPIS; DOGS; DRUG DESIGN; GLOMERULAR FILTRATION RATE; HEK293 CELLS; HUMANS; KIDNEY FUNCTION TESTS; MALE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, C-TYPE; NATRIURETIC PEPTIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RENAL AGENTS; SNAKE VENOMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84988824975     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvv040     Document Type: Article

References (34)

1. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52:60-68.
2. Francis GS. From B-type natriuretic peptide to green mambas: the process of discovery. J Am Coll Cardiol 2008;52:69-70.
3. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr. Pharmaco-dynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009;49:668 - 673.
4. McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep 2010;7:93-99.
5. Dickey DM, Burnett JC Jr, Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008;283:35003-35009.
6. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y, Kangawa K. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003;144:2279-2284.
7. Igaki T, Itoh H, Suga SI, Hama N, Ogawa Y, Komatsu Y, Yamashita J, Doi K, Chun TH, Nakao K. Effects of intravenously administered C-type natriuretic peptide in humans: comparison with atrial natriuretic peptide. Hypertens Res 1998;21:7 - 13.
8. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992;267:13928-13932.
9. Singh G, Maguire JJ, Kuc RE, Skepper JN, Fidock M, Davenport AP. Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation. Br J Pharmacol 2006;149: 838-844.
10. Vink S, Jin AH, Poth KJ, Head GA, Alewood PF. Natriuretic peptide drug leads from snake venom. Toxicon 2012;59:434-445.
11. Ichiki I, Huntley B, Soon P, Sangaralingham J, Sandberg S, Burnett JC Jr. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. J Mol Cell Cardiol 2014;75: 199-205.
12. Dickey DM, Potter LR. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol 2011; 51:67-71.
13. McKie P, Cataliotti A, Huntley B, Martin F, Olson T, Burnett JC Jr. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure lowering, renal enhancing and aldosterone suppressing actions. J Am Coll Card 2009;54:1024-1032.
14. Ogawa Y, Mukoyama M, Yokoi H, Kasahara M, Mori K, Kato Y, Kuwabara T, Imamaki H, Kawanishi T, Koga K, Ishii A, Tokudome T, Kishimoto I, Sugawara A, Nakao K. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol 2012;23: 1198-1209.
15. Martin FL, Sangaralingham SJ, Huntley BK, McKie PM, Ichiki T, Chen HH, Korinek J, Harders EJ, Burnett JC Jr. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS ONE 2012;7:e52422.
16. Thomsen K, Holstein-Rathlou NH, Leyssac PP. Comparison of three measures of proximal tubular reabsorption: lithium clearance, occlusion time, and micropunc-ture. Am J Physiol 1981;241:F348-F355.
17. Marqulies KB, Heublein DM, Perrella MA, Burnett JC Jr. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol 1991;260:F562 - F568.
18. ′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 1996;50:1718-1725.
19. Kaczmarczyk J, Kruttgen CJ. Eine einfache colorimetrischemethode zur inulinbes-timmung fu?r Nierenclearanceuntersuchungen bei Stoffwechselgesunden und. Diabetikern Kim Wochenschr 1955;33:729-730.
20. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009;(191):341-366.
21. Pankow K, Schwiebs A, Becker M, Siems WE, Krause G, Walther T. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol 2009;393:496-503.
22. Ogawa H, Qiu Y, Ogata C, Misono K. Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain: rotation mechanism for trans-membrane signal transduction. J Biol Chem 2004;279:28625-28631.
23. Van Kimmenade RR, Januzzi JL Jr. The evolution of the natriuretic peptides - current applications in human and animal medicine. J Vet Cardiol 2009;11:S9-21.
24. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993;291:83-88.
25. Doi K, Ikeda T, Itoh H, Ueyama K, Hosoda K, Ogawa Y, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Fukunaga Y, Saito T, Sone M, Yamahara K, Kook H, Komeda M, Ueda M, Nakao K. C-type natriuretic peptide induces rediffer-entiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 2001;21:930-936.
26. Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki T, Harders GE, Chen HH, Burnett JC Jr. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide. Hypertension 2011;57: 201-208.
27. Burnett JC Jr, Granger JP, Opgenorth TF. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984;247:F863 - F866.
28. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, Hammer RE, Herz J, Kuhn M. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci USA 2002;99:7142-7147.
29. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
30. Letts G, Loscalzo J. Frontiers in nephrology: targeting inflammation using novel nitric oxide donors. J Am Soc Nephrol 2007;18:2863-2869.
31. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the “real world” of therapy. Circ J 2005;69:283-290.
32. O'Connor C, Starling R, Hernandez A. Nesiritide in acute decompensated heart failure. N Engl J Med 2011;365:32-43.
33. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Belohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131:54-61.
34. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, DiMarchi R, Tschöp MH. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5: 749-757.